Shop ASCO Optimum Imaging Strategies for Advanced Prostate Cancer

Optimum Imaging Strategies for Advanced Prostate Cancer

Published: January 2020
$9.95
Print Copy Information:
  • 8 pages
  • Multifold
  • 80# Aqueous Coating
  • 4.25" x 7.25"
  • Ships in 5 – 10 business days
Add to Cart
What's Inside
Bulk and Institutional Ordering
About the Authors
Additional Information

A digital version of this pocket guide is available for FREE at this link

  • Introduction
  • Treatment Recommendations
    • Newly Diagnosed Clinically High-Risk/Very High-Risk Localized Prostate Cancer
      • Conventional imaging negative
      • Conventional imaging suspicious/equivocal
      • Rising PSA after prostatectomy and negative conventional imaging (either initial PSA undetectable with subsequent rise or PSA never nadirs to undetectable)
      • Rising PSA after radiotherapy and negative conventional imaging
      • Metastatic prostate cancer at initial diagnosis or after initial treatment, hormone sensitive
      • Non-metastatic CRPC (nmCRCP)
    • Metastatic CRPC
      • PSA progression
      • Radiographic progression on conventional imaging
  • Algorithms
    • Imaging Algorithm for High/Very High-Risk Disease at Initial Ptresentation (per National Comprehensive Cancer Network [NCCN])
    • Imaging algorithm for patients with rising prostate-specific antigen (PSA) after local treatment
  • For purchases under 100 in quantity, we suggest placing the order directly through the website.
  • We offer group/institutional licenses for multi-user accounts (discount amount varies depending on the number of users).
  • We are proud to offer special discounts to medical schools, training programs, students and more.
  • We offer bulk purchase discounts based on number of copies and number of titles.

Contact Us for more details

Founded in 1964, the American Society of Clinical Oncology is the world's leading professional organization for physicians and oncology professionals caring for people with cancer.

Description

This pocket guide is derived from recommendations in the American Society of Clinical Oncology Guideline. This resource is a practice tool based on ASCO® practice guidelines and is not intended to substitute for the independent professional judgment of the treating physician. Practice guidelines do not account for individual variation among patients. This pocket guide does not purport to suggest any particular course of medical treatment. Use of the practice guidelines and this resource are voluntary. The practice guidelines and additional information are available at www.asco.org/supportive-care-guidelines. Copyright © 2021 by American Society of Clinical Oncology. All rights reserved.

You can also find this product included in this bundle!

ASCO Guidelines Bundle

American Society of Clinical Oncology
Last Updated: Dec 16, 2024
$ 853.95 Print Included Guidelines:
  • Adjuvant Bisphosphonates and Other Bone-Modifying Agents in Breast Cancer
  • Adjuvant Therapy for Stage III Colon Cancer
  • Advanced Gastroesophageal Cancer
  • Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer
  • Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer – Brain Metastases
  • Antiemetics
  • Antimicrobial Prophylaxis for Adult Patients With Cancer-Related Immunosuppression
  • Antineoplastic Therapy Administration Safety Standards for Adult and Pediatric Oncology
  • Anxiety and Depression in Adult Survivors of Cancer
  • Appropriate Systemic Therapy Dosing for Obese Adult Patients with Cancer
  • Axilla Management in Early-Stage Breast Cancer
  • Biomarkers for Adjuvant Endocrine and Chemotherapy in Early-Stage Breast Cancer
  • Biomarkers for Systemic Therapy in Metastatic Breast Cancer
  • Bone-Modifying Agents in Metastatic Breast Cancer
  • Bone-Modifying Agents in Multiple Myeloma
  • Breast Cancer Germline Testing
  • Cancer Survivorship for People Affected by Advanced or Metastatic Cancer
  • Cancer-Associated Anemia With Erythropoiesis-Stimulating Agents
  • Cannabis in Adults with Cancer
  • Cardiac Dysfunction - Prevention and Monitoring in Cancer Survivors
  • Cervical Cancer Prevention
  • Chemotherapy in Combination With Radiotherapy for Definitive-Intent Treatment of Stage II-IVA Nasopharyngeal Carcinoma
  • Chemotherapy-Naïve Castration-Resistant Prostate Cancer
  • Chronic Pain in Survivors of Adult Cancers
  • Clear Cell Renal Cell Carcinoma
  • Colorectal Cancer Biomarkers
  • Colorectal Cancer Early Detection
  • Diagnosis and Management of Squamous Cell Carcinoma of Unknown Primary in the Head and Neck
  • Diffuse Astrocytic and Oligodendroglial Tumors in Adults
  • Early-Stage Breast Cancer
  • Estrogen and Progesterone Receptor Testing in Breast Cancer
  • Exercise, Diet, and Weight Management During Cancer Treatment
  • Fatigue in Adult Survivors of Cancer
  • Fertility Preservation
  • Germline and Somatic Tumor Testing in Epithelial Ovarian Cancer
  • Germline Genetic Testing for Cancer
  • Hepatitis B Virus Screening and Management for Patients with Cancer Prior to Therapy
  • HER2 Testing in Breast Cancer
  • Hormone Receptor–Positive Breast Cancer Adjuvant Endocrine Therapy
  • HR-Positive, HER2-Negative Metastatic Breast Cancer
  • Immune-related Adverse Events from Immune Checkpoint Inhibitor Therapy
  • Immune-related Adverse Events — CAR T-Cell Therapy
  • Initial Management of Noncastrate Advanced, Recurrent, or Metastatic Prostate Cancer
  • Integrative Medicine for Pain Management in Oncology
  • Integrative Oncology Care of Symptoms of Anxiety and Depression in Adult Patients with Cancer
  • Invasive Cervical Cancer
  • Laryngeal Cancer
  • Late-Stage Colorectal Cancer
  • Locally Advanced Rectal Cancer
  • Lung Cancer Surveillance After Definitive Curative-Intent Therapy
  • Malignant Pleural Mesothelioma
  • Management of Cancer Cachexia
  • Management of Dyspnea in Advanced Cancer
  • Management of Hereditary Breast Cancer
  • Management of Male Breast Cancer
  • Management of Osteoporosis
  • Management of Salivary Gland Malignancy
  • Management of the Neck in Squamous Cell Carcinoma of the Oral Cavity and Oropharynx
  • Medication-Related Osteonecrosis of the Jaw
  • Metastatic Colorectal Cancer
  • Metastatic HER2-Negative Breast Cancer – Chemo- and Targeted Therapy
  • Metastatic Pancreatic Cancer
  • Metastatic Well-differentiated Gastroenteropancreatic Neuroendocrine Tumors
  • Molecular Biomarkers in Localized Prostate Cancer
  • Multiple Myeloma
  • Neoadjuvant Chemotherapy for Newly Diagnosed, Advanced Ovarian Cancer
  • Neoadjuvant Chemotherapy, Endocrine Therapy, and Targeted Therapy for Breast Cancer
  • Non-Small Cell Lung Cancer — Adjuvant Therapy for Completely Resected Stages I-IIIA
  • Optimum Imaging Strategies for Advanced Prostate Cancer
  • Osteoradionecrosis in Patients With Head and Neck Cancer
  • Outpatient Management of Fever and Neutropenia in Adults Treated for Malignancy
  • Ovarian Masses and Treatment of Epithelial Ovarian Cancer
  • Palliative Care
  • Palliative Care in the Global Setting
  • Pancreatic Cancer - Evaluating Susceptibility
  • PARP Inhibitors in the Management of Ovarian Cancer
  • Penile Cancer
  • Platelet Transfusion
  • Potentially Curable Pancreatic Adenocarcinoma
  • Prevention And Management Of Chemotherapy-Induced Peripheral Neuropathy In Survivors Of Adult Cancers
  • Recurrent and Metastatic Head and Neck Cancers
  • Resected Biliary Tract Cancer
  • Role of Treatment Deintensification in the Management of p16+ Oropharyngeal Cancer
  • Salivary Gland Hypofunction and/or Xerostomia
  • Secondary Prevention of Cervical Cancer
  • Selection of Optimal Adjuvant Chemotherapy and Targeted Therapy for Early Breast Cancer
  • Small Renal Masses
  • Somatic Genomic Testing for Metastatic or Advanced Cancer
  • Stage II Colon Cancer Adjuvant Therapy
  • Stage III Non-Small Cell Lung Cancer
  • Stage IV Non-Small Cell Lung Cancer without Driver Alterations
  • Systemic Therapy for Advanced Hepatocellular Carcinoma
  • Systemic Therapy for Melanoma
  • Systemic Therapy for Small Cell Lung Cancer
  • Systemic Therapy for Stage I–III Anal Squamous Cell Carcinoma
  • Systemic Treatment of Patients With Metastatic Breast Cancer
  • Therapy for Stage IV Non-Small-Cell Lung Cancer With Driver Alterations
  • Treatment for Brain Metastases
  • Treatment of Early-Stage Colorectal Cancer
  • Treatment of Locally Advanced Esophageal Carcinoma
  • Treatment of Metastatic Carcinoma and Myeloma of the Femur
  • Use of Endocrine Therapy for Breast Cancer Risk Reduction
  • Use of Opioids for Cancer Pain
  • Vaccination of Adults with Cancer
  • Venous Thromboembolism Prophylaxis and Treatment in Patients with Cancer
  • Vulnerabilities in Older Patients Receiving Systemic Cancer Therapy
  • White Blood Cell Growth Factors
Add to Cart
Need help?